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Abstract
The rod-shaped nanoparticles of the widespread plant pathogen tobacco mosaic virus (TMV) have been a matter of intense debates
and cutting-edge research for more than a hundred years. During the late 19th century, their behavior in filtration tests applied to the
agent causing the 'plant mosaic disease' eventually led to the discrimination of viruses from bacteria. Thereafter, they promoted the
development of biophysical cornerstone techniques such as electron microscopy and ultracentrifugation. Since the 1950s, the
robust, helically arranged nucleoprotein complexes consisting of a single RNA and more than 2100 identical coat protein subunits
have enabled molecular studies which have pioneered the understanding of viral replication and self-assembly, and elucidated
major aspects of virus–host interplay, which can lead to agronomically relevant diseases. However, during the last decades, TMV
has acquired a new reputation as a well-defined high-yield nanotemplate with multivalent protein surfaces, allowing for an ordered
high-density presentation of multiple active molecules or synthetic compounds. Amino acid side chains exposed on the viral coat
may be tailored genetically or biochemically to meet the demands for selective conjugation reactions, or to directly engineer novel
functionality on TMV-derived nanosticks. The natural TMV size (length: 300 nm) in combination with functional ligands such as
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peptides, enzymes, dyes, drugs or inorganic materials is advantageous for applications ranging from biomedical imaging and
therapy approaches over surface enlargement of battery electrodes to the immobilization of enzymes. TMV building blocks are also
amenable to external control of in vitro assembly and re-organization into technically expedient new shapes or arrays, which bears a
unique potential for the development of 'smart' functional 3D structures. Among those, materials designed for enzyme-based biode-
tection layouts, which are routinely applied, e.g., for monitoring blood sugar concentrations, might profit particularly from the pres-
ence of TMV rods: Their surfaces were recently shown to stabilize enzymatic activities upon repeated consecutive uses and over
several weeks. This review gives the reader a ride through strikingly diverse achievements obtained with TMV-based particles,
compares them to the progress with related viruses, and focuses on latest results revealing special advantages for enzyme-based
biosensing formats, which might be of high interest for diagnostics employing 'systems-on-a-chip'.
Introduction
In the early years of virology, viruses were primarily regarded
as small infective agents sometimes causing fatal diseases.
Today, viruses and virus-like particles (VLPs) are seen in a dif-
ferent light by a steadily growing scientific community: A
broad scope of interest was shifted towards the application of
spherical and elongated viruses in nanotechnology [1-5]. As
several viral particle types are supramolecular complexes of
well-defined shapes and dimensions, and with numerous specif-
ically addressable coupling sites exposed on their outer and
sometimes inner surfaces, they offer intriguing possibilities for
use as nanocontainers for the encapsidation or fabrication of
compounds, or as nanofiber scaffolds for the immobilization
and presentation of functional units. Most of the novel ap-
proaches make use of plant or bacterial viruses non-pathogenic
for warm-blooded animals, or of non-infectious virus shells
which lack part or all of the viral genome. Several viruses may
be genetically engineered to increase the number of selectively
addressable binding sites, or to alter specific properties of the
template [6,7]. Principal players in virus-based nanotechnology
are cowpea mosaic virus (CPMV), cowpea chlorotic mottle
virus (CCMV), potato virus X (PVX), the bacteriophages MS2
and M13 and tobacco mosaic virus (TMV; for a list of abbrevi-
ations, see Table 1) [1,4,6,8]. The application possibilities for
viruses are as versatile as the composition of the interdiscipli-
nary teams working on them. In the following, we report on
trends in the gradually changing field of research on virus and
virus-like particles, with special focus on the well-known TMV
nanosticks and their use as nanostructured scaffolds for the effi-
cient and advantageous display of biomolecules, namely of
active enzymes.
Review
From virus discovery to current research
trends
Around the turn of the 19th century, a new type of infectious
agent, the 'virus', was discovered [9,10]. During the following
decades it was proven that all viruses consist of genetic DNA or
RNA material surrounded by a protein coat (capsid), and
optionally a lipid envelope. Since virus genomes do not encode
all biochemical mechanisms necessary for their own replication
and spread, they exploit the genetic repertoire of the infected
host cells, which are re-programmed to produce many thou-
sands of virus copies. Viruses have been discovered in virtually
all types of organisms, with numerous well-characterized
species adapted to animals, plants, fungi, or prokaryotic bacteria
or archaea. As they may have an enormous impact on the physi-
ological status and health of the host, viruses were originally
defined and classified in regard to the diseases provoked, and to
their minuscule size due to which they passed sterilization
filters. The second half of the 20th century is often referred to
as "the golden age of virology": During these decades, several
Nobel Prizes were awarded for the description of new viruses
and important insights into the characteristics of virus–cell
interactions [11]. A virus taxonomy with a constantly devel-
oping classification and nomenclature was introduced by the
International Committee on Taxonomy of Viruses (ICTV) [12].
The most recent ICTV report from the end of 2011 [13] lists
87 families with 2,284 virus and viroid species and many yet
unassigned viruses, which had increased to 3,186 species by
end of 2015 [14]: The identification of further viruses is accel-
erating rapidly due to next generation sequencing techniques
revealing a plentitude of so far unknown, often inconspicuous
viruses in the environment. With the growing knowledge on
virus diversity it becomes more and more obvious that numer-
ous species are not associated with any disease, and others even
exert positive effects on their hosts [10,15]. Viruses also con-
tribute substantially to the horizontal exchange of genetic mate-
rial not only within a single host species, but even between
genomes of distinct organisms susceptible to the same virus
[16]. Hence the discipline of virology experiences intense novel
research activities towards a better understanding of the evolu-
tionary roles and individual capacities of distinct viruses, and
the mutual interactions between virus populations and commu-
nities ('viromes'), hosts and their environments. Concurrently,
remarkable progress has been made in the investigation of
natural multifunctional complexes, and the development of
'smart' hybrid structures with elaborate functionalities
exploiting biologically optimized principles. As these are
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Table 1: Abbreviations of biological/biochemical building blocks at a glance.
abbreviation description
4CL2 4-coumarate:CoA-ligase 2
ABTS 2,2′-azino-bis[3-ethylbenzothiazoline-6-sulphonic acid] (chromogenic HRP substrate)
A-protein small oligomers of tobamoviral CP subunits
'Biotin-' 'maleimide-PEG11-biotin linker-' (in compound forms: biotin linker-equipped unit)
CALB Pseudozyma (Candida) antarctica lipase B
CCMV Cowpea chlorotic mottle virus
CPMV Cowpea mosaic virus
CP coat protein
CPCys/Bio coat protein of TMVCys, equipped with biotin linker






ICTV International Committee on Taxonomy of Viruses
OAs origin of assembly (RNA sequence nucleating tobamovirus self-assembly)
PDMS poly(dimethylsiloxane)
PVA Potato virus A




Sec selenocysteine (cysteine analogue with selenol in place of thiol, in selenoenzymes)
STS stilbene synthase
TLP TMV-like particle
TMV Tobacco mosaic virus (nanotubular, 'rod-shaped' nucleoprotein particle)
TMVCys TMV particles containing S3C-mutant CPs exposing a thiol on every CPCys
TMVCys/Bio TMVCys equipped with [maleimide-coupled]-PEG11-biotin linkers
tobamovirus plant virus genus (taxonomic group, type member: tobacco mosaic virus)
VLP virus-like particle
ZYMV Zucchini yellow mosaic virus
sought-after especially for novel miniaturized devices and hier-
archically organized materials, a second strikingly expanding
field in contemporary virus research addresses both organiza-
tion and re-design of viral nanoparticles. As introduced above,
these are attracting special attention as multivalent shells
enabling an encapsidation, presentation and delivery of func-
tional molecules in different setups, and as building blocks of
nanoarchitectures performing complex tasks up to biochemical
conversion. Most suited in this context are robust, self-assem-
bling viruses non-pathogenic for mammals and their bacterial
flora such as TMV.
Tobacco mosaic virus
Historic cornerstones
The first plant virus ever described was the Tobacco mosaic
virus (TMV; genus: Tobamovirus, family Virgaviridae [17]). In
1886, Adolf Mayer reported on a disease that had occurred for
many years in tobacco cultivated in Holland, which was mani-
fested by stunting and leaf symptoms including brittleness and a
mosaic-like color variegation of light and dark green (Figure 1).
Therefore he named the syndrome “tobacco mosaic” [18]. A
few years later, Dimitri Ivanowski revealed that the extracts of
mosaic-affected leaves remained infective after passage through
bacteria-excluding filters [19]. Martinus Beijerinck, while
repeating Ivanowski´s experiments, recognized that he was
dealing with a pathogen of a novel type, much smaller than a
bacterium, which he called “virus” in 1898 to indicate its non-
bacterial nature [20-22].
From 1935 on, Wendell Stanley examined the tobacco and a
similar tomato disease and attributed them to an infectious crys-
tallizable protein [23,24]. Soon thereafter, Bawden and
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Figure 1: Tobacco mosaic virus infection. Left: Leaf of a healthy tobacco plant (Nicotiana tabacum 'Samsun' nn). Center: Leaf of a TMV-infected plant
showing the typical TMV-associated mosaic (light and dark green mottling on the leaf blade). Right: Organization and dimensions of a TMV ribonucle-
oprotein particle, with the RNA not depicted as it is completely enclosed in the CP helix (golden).
co-workers detected a nucleic acid fraction of about 5% in the
fibrous crystals [25,26]. These were shown by Helmut Ruska
and colleagues, who pioneered electron microscopy in Berlin at
that time, to most likely consist of rods about 300 nm in length
and 15 nm in diameter [27]. In the 1950s, cutting-edge X-ray
diffraction studies along with intense scientific interactions of
James Watson, Rosalind Franklin and Donald Caspar revealed
the first major clues of the helical organization of the TMV
nucleoprotein particles (for a thorough historic overview see
[28]). They localized the viral genomic RNA strand wrapped in
a helix of more than 2000 identical coat protein (CP) subunits,
enclosing a hollow longitudinal channel of 4 nm diameter (see
below, and Figure 1). The assembly mechanism of these nano-
tubes was a subject of intense research up to the late 1970s,
with still some debate on details and putative different modes
going on (see [29-32] for original research or for extensive
reviews [33-36]). Concomitantly, infectivity and genetic organi-
zation of the viral RNA as well as the CP amino acid sequence
were determined as reviewed in detail [37], with the complete
RNA sequence published in 1982 [38]. Summing up, TMV was
the first plant virus of which a highly resolved particle structure
including the amino acid sequence of its protein, and all major
gene functions had been unraveled. Furthermore, it was the first
of all viruses with both assembly and disassembly shown to
take place in vivo and, under suitable conditions, also in vitro
[34,37,39-41]. TMV thus played a key role in the origin of the
virology discipline [21], and in the advancement of bioanalyt-
ical technologies, with an exciting body of literature elabo-
rating specific aspects [28,42,43].
Particle structure and assembly
TMV is a supramolecular ribonucleoprotein tube of
ca. 2130 identical CP subunits, organized as a continuous right-
handed helix enclosing a single-stranded viral RNA of
6395 nucleotides, which is helically integrated between the pro-
teins and thus completely protected [44-46]. Each CP subunit
consists of 158 amino acids. Numerous studies have investigat-
ed the self-assembly of TMV in vitro and provided many pieces
of the puzzle, with most of them evidencing a bidirectional tube
growth starting at an origin of assembly (OAs) site in the
3'-portion of the viral RNA [33,47], as illustrated in Figure 2.
Depending primarily on pH, ionic strength, and total protein
concentration, CPs may form small oligomers collectively
known as "A-protein". This aggregation of TMV protein in the
absence of RNA is mainly driven by hydrophobic interactions.
CPs further assemble into higher-order ring-shaped aggregates
of 34 subunits, each containing two layers of 17 molecules.
These double-layered “disks” are essential for the nucleation of
TMV particle assembly in vitro, as they may undergo a confor-
mational change into a short helical “lockwasher” [33,48]. Most
likely, the interaction of a disk with a specific RNA stem-loop
of the OAs [49-52] triggers its transformation into the helical
state, thereby threading the 5’-portion of the RNA into the
nascent protein helix. It becomes incorporated between the CP
layers and will form a “traveling loop” accessible on the “top”
end of the particle [35]. Starting from this nucleation complex, a
fast cooperative growth towards the 5’-tail occurs by serial ad-
dition of further “disks” and concomitant packaging of the
5'-segment of the RNA, which is drawn “up” through the
central channel. Simultaneously, the 3'-portion of the RNA is
encapsidated, but in a slower manner by the incorporation of
small CP aggregates or “A-protein”. Several comprehensive
reviews provide the details [33,35,36,47,50].
The complete final particle is 300 nm long, with an outer diam-
eter of 18 nm and a central channel of 4 nm diameter [53]. With
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Figure 2: Self-assembly process of TMV. Model for the bidirectional self-assembly of nanotubular TMV particles, based on the formation and
consumption of different CP oligomers, i.e. "A-protein" and disks, in vitro. RNA is shown as a black line. Assembly of TMV starts with insertion of the
RNA origin of assembly (OAs)-loop into the central hole of a protein disk, resulting in its conformational change into a helical “lockwasher” and the for-
mation of an RNA “traveling loop” (indicated with arrow) and integration of the adjacent RNA portion between the CP layers. Fast tube elongation
towards the 5’-tail of RNA is achieved by the serial addition of protein disks, while slow 3'-elongation occurs through use of “A-protein”. Modified from
[35].
the aid of modified RNA molecules, TMV-like particles (TLPs)
of altered length, or non-linear more complex structures up to
branched architectures may be generated [54-59]. Furthermore,
it is possible to immobilize one end of the RNA template prior
to its encapsidation by CP, resulting in TLP growth bottom-up
at sites of interest [54,57,60]. Finally, different TMV CP vari-
ants (mixed or arranged in domains) can be combined in
single particles, which then may expose distinct chemically
addressable surface groups [61,62]. This tunability in shape
and biochemical properties makes TMV derivatives particular-
ly versatile biotemplates for the fabrication of hybrid
nanostructures and the high-density presentation of functional
compounds.
New applications of viruses in
nanotechnology
Virus-based nanotechnology
In addition to virological research in the original sense, investi-
gating, e.g., virus structure, replication, spread, or interactions
with host cells and tissues, viruses and VLPs have been
regarded as a new class of biomaterials with an immense poten-
tial for applications as templates, building blocks and “smart”
tools in chemical synthesis, medicine and nanotechnology since
the turn of the century [1-4,63,64]. Several virus types exhibit
high stability and precise 3D structures and dimensions with
well-defined interior and exterior surfaces. Some of them are
accessible to controlled modifications and production in large
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Figure 3: Fabrication of distinct types of viral capsids engineered for various applications. Virus particles of both spherical and helical shapes are
accessible to a wide range of modifications, making them versatile tools e.g. for chemical synthesis, medical imaging or drug delivery applications,
and biotemplates of variable shapes to serve as nanocarriers for functional units and building blocks of extended hybrid materials. Reproduced with
permission from [6], copyright 2014 Springer.
quantities from renewable resources. These are being tested ex-
tensively as scaffolding biotemplates in various applications,
ranging from biosensing to tumor therapeutics. Hence, in the
recent past, the number of reports on the successful construc-
tion of advantageous virus-derived hybrid materials and devices
has been growing rapidly and reviewed extensively [5,7,8,65-
70]. Most viruses utilized as biological building blocks are plant
or bacterial viruses of either spherical (quasi-icosahedral) or
fiber/rod shape (helical symmetry), with the application
perspectives differing in certain aspects for these two types of
backbones (as illustrated in Figure 3 and some review articles
[6,71,72]). Although they have in common that they are non-
pathogenic for humans and animals, spherical plant viral or
bacteriophage particles serve predominantly as nanocontainers
for cargo or reaction vessels, and as presentation systems for
bio-effective molecules such as antigens, whereas rod and fila-
mentous backbones excel in the particle structures available,
and the dense exposure of docking and chemically reactive sites
attainable on their outer coat.
The functional molecules immobilized on, or encapsulated in
viral capsid comprise, amongst many others, fluorescent dyes
for imaging purposes either tracing the virus itself, or targeting
specific cells or organs [73-76], antigens for the development of
vaccines as reviewed in great detail [77-79], drugs or imaging
reagents for increasingly elaborated biomedical applications
[80-82] with numerous further examples described in overview
articles [70,72,83-86], antibodies as virus-based tracers [65],
immunoadsorbents [87] or molecular stickers [88], to name but
a few examples. Much effort is also directed towards the fabri-
cation of nanostructured hybrid materials with improved or
novel chemical and physical properties, based on the combina-
tion of a multitude of synthetic and inorganic compounds with
virus assemblies [5,7,68,69,89,90].
Application of TMV-/tobamovirus-based structures
In these recent developments, TMV with its rigid, self-assem-
bling nucleoprotein capsid continues to play a leading role
among the most promising viral backbones [5,7,91,92]. TMV
and closely related tobamoviruses have been applied as versa-
tile templates for the metallization or mineralization of their
inner or outer surfaces, respectively, yielding nanosized compo-
nents for, e.g., electronic devices, batteries, photoelectrochem-
ical cells or environmental remediation [63,93-113], as scaf-
folds for the display of reporter dyes, nanoparticles or contrast
agents such as gadolinium complexes, for light harvesting,
energy conversion, plasmonics or magnetic resonance imaging
[82,92,100,114-121], and as carrier rods for effector peptides
for distinct purposes from affinity binding, intravital targeting
up to cell-culture supports [105,111,117,122-124], or as anti-
gens for vaccination [125-129]. Finally, the exposure of en-
zymes or biocatalytically active domains on the TMV surface is
an area of intense research, since the viral nanoparticles are ex-
pected to offer specific advantages over conventional immobili-
Beilstein J. Nanotechnol. 2016, 7, 613–629.
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Figure 4: TMV and related tobamoviruses: versatile templates for the construction of biohybrid nanoobjects and nanostructured materials for a wide
range of applications exemplified schematically. Among numerous reports on respective approaches, the following references may illustrate selected
specific achievements and strategies: [a] = [113,133]; [b] = [132,134]; [c] = [57,58,87]; [d] = [54,61,135-137]; [e] = [116-118,121,124]; [f] = [125-
127,129,138]; [g] = [122,123,139,140]; [h] = [59]; [i] = [107,141]; [k] = [119,120]; [m] = [93-96,98,99,102,105,111]; [n] = [109]; [o] = [103,110,112].
zation matrices [130,131]. These approaches, however, bear
special challenges as genetic fusions to the TMV CP are toler-
ated only to a limited extent [47,88,131]. That is why up until
now, the number of respective studies is low, though particular-
ly promising [132,133], as described in the following. The
manifold functionalization and assembly procedures applied to
tobamoviral scaffolds have yielded a multiplicity of biohybrid
nanostructures for strikingly different uses, as illustrated by
Figure 4, which also provides corresponding references.
Enzymes presented by viral carrier templates:
promises, limits and prospects
Enzymes are extensively used in the industrial fabrication of
chemicals and pharmaceuticals as well as in analytical routines.
There is a considerable interest to steadily increase productivity
by optimizing process conditions, engineering the operational
performance of the enzymes, and improving immobilization
techniques towards a better handling of fully active enzyme
preparations. A broad range of different immobilization
methods is applied, ranging from protein adsorption, covalent
coupling, entrapment and encapsulation to intermolecular cross-
linking with filler components, specific high-affinity docking
and combinations thereof [142-144]. Enzymes installed on solid
supports often exhibit enhanced stability, in comparison to their
soluble counterparts [145,146]. One important additional aspect
is their simple separation from the reaction solution and the re-
sulting reusability [147]. On the other hand, immobilization
may lead to reduction or even complete loss of enzymatic activ-
ity [148], as a result of conformational changes or blockage of
the active sites due to interactions with the coupling matrix
[149-151]. Therefore, advantageous strategies to immobilize
and present enzymes in a predictable and sterically favorable
orientation at high surface densities are desired. Virus-derived
templates appear to be among the best-suited carrier backbones
in this context, since they provide all prerequisites to achieve
tight positional control of the bioactive units [130], and may
ensure optimal steric accessibility of the catalytic centers if
protruding into the reaction liquid. This would be realized best
with rigid rod-like carrier objects such as TMV and TLPs
deduced thereof.
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Up to now, however, the application of viral scaffolds for
the presentation of enzymes on their outer surfaces has rarely
been investigated, though with promising prospects in most of
the few cases published [88,132,152-155]. By contrast, enzyme
encapsulation inside viral cavities is a matter of much broader
research [72,156,157], in analogy to synthetic polymersomes
that are tested extensively for uses as nanoreactors [158-161].
This article delivers insight into recent achievements on TMV-
derived carrier rods equipped with biological enzymes. First,
though, a glance at the other successfully established hybrid
complexes of elongated plant viruses fashioned with active en-
zymes introduces typical obstacles. As explained thoroughly by
Cardinale and co-workers [130] and by Pille et al. [88], a major
problem lies in the low tolerance of most such viruses for
accepting major alterations of their CPs, including extensions
and charge modifications. Viral filaments containing a single,
densely packed protein species are especially prone to struc-
tural disturbances, which may abolish assembly of the viral par-
ticles due to steric constraints. This often promotes back muta-
tions and thus loss of engineered CP domains. Furthermore,
changes of the viral surface may also provoke defense reactions
up to tissue necrosis aborting viral multiplication, which has
been analyzed in detail especially for TMV [47]. Consequently,
direct genetic fusion of enzyme sequences to the ends, or into
exposed loops, of viral CPs frequently failed, and also short
peptide tags enabling bioaffinity linkage were inserted only
occasionally [87,94,134,162]. Heterologously expressed TMV
CP species offer more degrees of freedom for modifications.
However, CP from E. coli does not organize into TLPs with
RNA efficiently since it lacks an N-terminal post-translational
acetylation; and up to now the yield of TLPs from eukaryotic
yeast cells is relatively low [55]. Hence ectopically produced
TMV templates are not yet accessible. Finally, an attachment of
functional molecules to virus surfaces equipped too densely
with anchoring tags may also be inefficient.
For these reasons, previous work on elongated viral enzyme
carriers succeeded only if elaborate conjugation strategies were
applied, addressing a subset of the viral CPs or introducing
connector molecules. Direct genetic extension of about 60% of
the roughly 1,300 CP subunits of PVX (genus: Potexvirus) with
Pseudozyma (Candida) antarctica lipase B (CALB) was
achieved by help of the ribosome “skip” mechanism ([154] and
T. Michon, personal communication), which is attained by foot-
and-mouth-disease virus (FMDV) 2a peptide-like junctions
[73,163]. Although the enzyme CALB underwent a 45-fold de-
crease in activity, it functioned stably on the plant viral back-
bone. The use of antibodies as “molecular stickers” and thus
spacers was developed into a partially universal coupling
concept to viral templates [88]: It allows for the stable binding
of functional proteins fused with the Z33 peptide (derived from
staphylococcal protein A [164]) to the Fc portions of
immunoglobulins IgG1, of which high-affinity species directed
against various virus types are available. By these means, a
fully active 4-coumarate:CoA-ligase 2 (4CL2; N-terminally
fused to Z33) was installed on a distinct filamentous plant virus,
zucchini yellow mosaic virus (ZYMV, genus: Potyvirus), with
almost 90% surface coverage [88]. This work has recently been
extended to a related potyvirus, potato virus A (PVA), which
could be fashioned with similar surface density not only with
4CL2, but also with a two-enzyme mix of 4CL2 and stilbene
synthase (STS) expressed in E. coli, or with a fusion protein of
both partner enzymes [155]. The blended enzymes were able to
collaborate in a cascade reaction, converting p-coumaric acid
and further precursors into resveratrol. This polyphenolic com-
pound is well-known to wine connoisseurs, since it is found
predominantly in red grapes and wine and has been extensively
discussed to promote health. Although, to date, the fusion pro-
tein has not exhibited detectable activity on PVA, and the
resveratrol yield from the 4CL2/STS-PVA assemblies was rela-
tively low, the functionality of the enzyme cascade was clearly
demonstrated [155]. Further optimization and transfer to related
enzymes might therefore result in biological production plat-
forms for resveratrol or further “functional food” ingredients,
employing potato or other plant-virus derived biotemplates as
an immobilization matrix. The strategies shown to work for the
use of enzymes on TMV carrier particles are presented in more
detail in the next section.
TMV as carrier for biological enzymes
Linker-enabled bio-affinity coupling of enzymes to
TMV
A recent study sought to find out if the increasing use of rigid
TMV templates might also be extended to the immobilization of
enzymes [132], as demonstrated for flexuous PVX and ZYMV
particles. Since diagnostic assays could profit particularly from
novel nanosculptured high-density presentation platforms, a
glucose-sensing enzyme combination of glucose oxidase (GOx)
and signal-generating horseradish peroxidase (HRP) was
applied (see below in Figure 5 and Figure 6). Due to the prom-
ising and in part unexpected findings, some details of the ap-
proach are reported here exemplarily.
To circumvent the need for extensive changes to the natural
TMV structure, the enzymes were immobilized on the surface
of moderately engineered TMV sticks by a two-step procedure
[132]. This combined the covalent coupling of biotinylated
linkers to a tailored virus variant, and subsequent bioaffinity
binding of commercially available streptavidin [SA]-enzyme
conjugates (Figure 5A). A genetically modified TMV
(TMVCys) with a cysteine residue (S3C) surface-exposed
Beilstein J. Nanotechnol. 2016, 7, 613–629.
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Figure 5: TMV equipment with biotin linkers and [SA]-enzymes. A: Scheme of TMV functionalization. A coupling-competent TMV variant (TMVCys,
yellow) was coated with bifunctional maleimide-PEG11-biotin linkers resulting in TMVCys/Bio (green), followed by affinity binding of [SA]-enzymes
(purple). B: Selective linker coupling to CPCys (17.6 kDa) was possible with ca. 50% efficiency, as shown by specific gel shift of the CPCys band
(CPBio). Molecular weight marker bands as indicated (15% SDS-PAGE stained with Coomassie Brilliant Blue R250). C: Transmission electron micros-
copy of TMVCys/Bio particles before and after binding of [SA]-enzymes (mix of [SA]-GOx:[SA]-HRP 14:1). The enzymes form a fluffy seam with protru-
sions, distributed over the whole particle length. Samples were adsorbed on Formvar®-coated carbon-sputtered copper grids and negatively stained
with 2% uranyl acetate; bars: 100 nm. Images show data obtained according to reference [132].
Figure 6: Influence of TMV adapter scaffolds on enzyme-based glucose detection layouts. A: Schematic drawing of different detection layouts using
TMV-derived or linker adapters for the immobilization of enzymes on solid supports, or adsorptively immobilized enzymes on untreated surfaces
(layouts with adapters: with TMVCys/Bio rods, CPCys/Bio aggregates, or biotin linkers; without adapters: plain surface). B: Catalytic activities achieved
with these layouts using different adapter concentrations, applying the same [SA]-GOx/[SA]-HRP input for colorimetric glucose detection via forma-
tion of ABTS* radicals (absorption maximum at λ = 405 nm). TMV adapter templates support the immobilization of substantially increased enzyme ac-
tivities. C: TMV adapters exert enzyme-stabilizing effects, increasing both the reusability of the immobilized enzyme upon hourly repeated uses (top),
and the storage stability over a testing period of three weeks. Initial turnover rates were set to 100 % and the percentage of remaining activities calcu-
lated. Degree of reusability: TMVCys/Bio nanorods > CPCys/Bio aggregates > biotin linker > substrate lacking any adapter molecule. For details, see
text and reference [132] for details. B/C: Reproduced according to the Creative Commons Attribution 4.0 International Public License from [132].
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nearby every CP N-terminus [61] served as a carrier rod with
more than 2,000 addressable thiols. These were equipped with
maleimide-reactive bifunctional linkers (maleimide-PEG11-
biotin; see [165] for details on bioconjugation techniques), re-
sulting in biotinylated TMVCys/Bio. The PEG11 linker spacer
provided increased degrees of freedom for a dense decoration
with [SA]-enzymes, and a spatial decoupling of the enzymes
and the TMV scaffold.
About 50% of the CPCys subunits could be decorated with
biotin linkers, and virtually all thereof with enzymes
(Figure 5B,C), resulting in complete coverage of the TMV
sticks by more than a single layer: The volume of all immobi-
lized enzyme molecules surpassed what was available directly
around the TMV surface. This indicated that the flexible spacer
arms of the linkers enabled a staggered high-density arrange-
ment of the enzyme conjugates.
The two-enzyme cascade system of GOx and HRP enabled a
colorimetric detection of catalytic activity and the quantifica-
tion of glucose [152,166,167]. Specifically, GOx catalyzes
glucose oxidation to D-glucono-1,5-lactone, thereby producing
hydrogen peroxide [168]. This is a substrate for HRP, which
reduces it to water, and, as a side reaction, can convert a
chromogenic substrate (e.g., tetramethylbenzidine TMB,
diaminobenzidine DAB, or 2,2′-azinobis[3-ethylbenzothiazoli-
nesulfonic acid] ABTS) into a colored product allowing for
spectrophotometric detection [169]. Partitioning experiments
tracing the fractionation of GOx/HRP activities after defined
[SA]-enzyme input revealed that enzyme binding to the
TMVCys/Bio sticks did not affect their performance [132].
Taken together, the technically simple linker-mediated affinity
binding of functional proteins turned out to be a straightfor-
ward approach for installing sensor enzymes on rigid TMV
nanorods: the two-step method achieved maximum surface
occupation with full enzymatic activity retained on the viral
backbones.
TMV adapter scaffolds conducive to biosensing
layouts
A main goal of the case study on TMV enzyme carriers was to
find out if biodetection setups would profit from an integration
of these multivalent nanobiotemplates, to increase the surface
density and/or steric accessibility of enzymatic sensor compo-
nents arranged thereon. Hence, the effects of two different
TMV-derived adapter scaffolds conveying specific binding of
[SA]-enzymes to conventional high-binding microtiter plates
were analyzed in colorimetric assays, detecting the generation
of ABTS* radicals (Figure 6). Equal enzyme input amounts
were applied into plate wells coated with (i) either fully assem-
bled biotinylated TMVCys/Bio adapter sticks, or (ii) released
lower-order CPCys/Bio aggregates, (iii) or stoichiometric
amounts of maleimide-PEG11-biotin linkers, respectively, or
into (iv) uncoated plates resulting in mere enzyme adsorption
(Figure 6A).
Assays in the presence of TMV adapters were substantially su-
perior to the other layouts: In parallel experiments with vari-
able adapter concentration, up to 45-fold higher substrate
turnover rates were achieved with rod templates, and up to
25-fold higher with CP aggregates, whereas corresponding
amounts of directly applied linkers resulted in a maximum
7-fold increase compared to the values obtained with directly
adsorbed enzymes. Hence, the virus templates allowed a partic-
ularly efficient immobilization of active enzymes and thus
strongly enhanced analyte turnover.
Beyond that, complete TMV rods exerted additional unfore-
seen beneficial effects on the performance of the enzymes. In-
creased reusability, greater stability, higher regenerability and
higher analysis rates; these are but a few of many benefits
appropriate enzyme immobilization routes may bring about
[145-147]. To gather information about putative advantageous
or deteriorating effects of TMV carriers on the long-term opera-
tion of sensor enzymes, the detection layouts in the absence and
presence of the different adapters were tested extensively for re-
usability and storage stability [132]. Upon repetitive hourly
uses, sample wells equipped with TMVCys/Bio adapter rods
exhibited remarkable remaining activities of around 90% upon
the sixth, and 75% upon the eighth use (Figure 6C, top).
Through three weeks of wet storage with 14 uses or idle, 40 to
50% of the glucose sensing activity was still retained
(Figure 6C, bottom and [132]). TMV CP aggregates were able
to stabilize the GOx/HRP system to a considerably lesser
extent, but significantly superior to plain biotin linkers, where-
as directly attached enzymes had lost detectable activities
already after the first testings. In conclusion, the surface of
assembled TMV rods seems to act as an activity-preserving
environment for sensor enzymes. In combination with the steri-
cally controlled high-density exposure possible on the nano-
structured TMV surface, TMV-like carrier architectures may
constitute supremely efficient immobilization supports worth
testing in further detection setups.
Making TMV an enzyme itself
The conformation of the densely packed CP subunits of TMV
rod and disk assemblies results in a surface-relief with regu-
larly ordered nanometric grooves and cavities (see [46] for the
most recent high-resolution cryo-EM reconstruction of TMV at
3.35 Å resolution). These have inspired a striking piece of in-
vestigation, as one of the repetitively arranged depressions
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Figure 7: Transformation of TMV CP molecules into enzymatically active rod-like assemblies. By exchanging suitably exposed natural surface
residues of a cysteine-free CP mutant for an Arg residue (interacting with reduced glutathione), and a Sec moiety introduced at a cysteine codon
through an auxotrophic bacterial expression system (by replacing canonical cysteine), GPx activity could be conferred to the TMV CP building blocks.
Under conditions favoring their self-assembly devoid of RNA, enzymatically active nanotubes with H2O2-reducing outer surfaces were generated.
Adapted with permission from [133], copyright 2012 American Chemical Society.
resembles the substrate-binding site of glutathione peroxidase
(GPx, EC 1.11.1.9), a natural selenoenzyme: Computer-aided
design identified adjacent, adequately positioned amino acids of
the viral CP which offered the chance to be modified into a
glutathione-attracting pocket containing a catalytic selenocys-
teine (Sec) moiety [133]. A corresponding project thus investi-
gated if by means of respective mutations, an appropriate TMV
CP variant could be transformed into an enzymatically active,
assembly-competent building block for the fabrication of TMV-
based artificial nanoenzymes mimicking GPx. This was real-
ized with convincing results by the replacement of a suitably
exposed serine by a cysteine residue, which then was equipped
with its analogue Sec through heterologous expression in a bac-
terial system auxotrophic in cysteine (Figure 7). Not only did
this protein organize itself into higher-order complexes under
suitable conditions, after trapping reduced glutathione (GSH),
the resulting disks or TMV-like nanotubes exhibited strong
H2O2-reducing GPx activity comparable to that of natural GPx
enzymes in the case of disk-like structures. The glutardialde-
hyde-stabilized complexes with multiple artificial biocatalyti-
cally active centers were shown to exert protective antioxidat-
ive effects on mitochondria, and might be of high value in bio-
sensor setups for the enzymatic detection of reactive oxygen
species [133]. Hence, the precise proteinaceous 3D structure of
TMV may even be converted into novel types of designer rods
with enzymatically active surfaces.
Perspectives on applicable TMV-assisted layouts
Among the many ideas about the technical uses of the rigid
TMV nucleoprotein tubes, those which employ manageable
amounts of viral templates and facile preparation strategies will
have the best prospects for realization. Based on the promising
findings on the performance of enzyme and antibody moieties
installed [87,132,134] or engineered [133] at high surface densi-
ties on TMV nanocarriers, miniaturized sensor devices might be
among the layouts worth extensive testing. Research on micro-
fluidic lab-on-a-chip biodetection systems started in the end of
the 20th century, and has been growing enormously since then
[170,171], which parallels the investigation of viral biotem-
plates (see above). The main emerging application area is
medical diagnostics, namely “point-of-care” on-site analytics
circumventing the need for expensive instrumentation [172],
with further uses becoming apparent in environmental, food, or
intoxication diagnostics (for a recent detailed review, refer to
[171]). Lab-on-a-chip solutions may integrate sample prepara-
tion and enrichment routines with multiple diagnostic tasks,
requiring low total amounts of analytes as well as biorecogni-
tion elements if high local concentrations are achieved. In this
regard, combinations of plant virus-based immobilization plat-
forms with accordingly designed flow cells, as indicated
schematically in Figure 8A, may be profitable and practicable.
Poly(dimethylsiloxane) (PDMS), a standard polymeric material
used for the fabrication of microfluidic devices by master-repli-
cation techniques, was already shown to allow a site-specific
bottom-up integration of TMV carrier sticks [60]. This was
achieved via isothiocyanate- (ITC-) based coupling of single-
stranded (ss) DNA anchors, subsequent trapping of the 3'-ends
of assembly-directing RNAs with OAs, and their encapsidation
by means of appropriate TMV CP preparations [54,60]. The re-
sulting arrays of 3'-terminally fixed nanosticks are then acces-
sible to biomolecule binding. Alternatively, pre-assembled
TMV sticks loaded with functional molecules may be
hybridized to ssDNA anchors after partial TMV disassembly,
exposing a 5'-terminal stretch of their RNA, e.g., under mild
alkaline conditions, as it has been demonstrated for TMV
labeled with distinct dyes [135,136]. This allows for the instal-
lation of blends of distinct TMV-exposed effector molecules (as
exemplified for [SA]-GOx/[SA]-HRP in Figure 8A), which is
of special interest for the construction of enzyme cascade reac-
tions, but also for multiplexing in advanced diagnostic ap-
proaches. Finally, adsorptive deposition of densely packed rod
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Figure 8: Prospects for novel layouts enabling lab-on-a-chip applications and improved orientation of enzymatically active TMV rods. A: Scheme of a
microchannel of a glucose sensor chip equipped with a blend of two TMV enzyme nanocarrier species. By an appropriate mixture thereof, an opti-
mally composed two-enzyme cascade of [SA]-GOx and [SA]-HRP can be established in a PDMS flow cell. B: TMV-like particles mounted in an upright
position in a nanowell template fabricated as follows: A flat substrate was equipped with ssDNA and covered with a 60 nm thin, perforated metal-
organic film produced by metal polymer blend lithography, followed by a metal-organic build-up reaction. OAs-containing RNA was subjected to
hybridization with DNA on the bottom of the holes, then assembly-competent CP was added to yield TMV-like rods within the pores. The AFM Image
(left) shows two TMV rods (black and red arrow) protruding from the 60 nm deep holes.
layers and three-dimensional assemblies was achieved for dif-
ferent TMV variants and solid supports, in some cases involv-
ing thiol bonding ([7,173] and references therein; [110,174-
176]).
So far, however, it remains to be tested whether TMV particles
immobilized via protruding RNA ends or through non-covalent
attachment would retain their arrangement inside the flow chan-
nels of microfluidic devices in operation (for typical layouts and
flow rates see [177]). To ensure robust implantation, full acces-
sibility and constant spacing, ongoing work is attempting to fix
TMV adapter sticks in upright positions. Initial results indicate
that nanopatterned metal-organic layers might enable a fine-
tuned adjustment of rod orientations in the desired dimensions
(Figure 8B): Substrates coated with DNA anchors were
equipped with a nano-perforated metal-organic layer via metal
polymer blend lithography [178,179], and its topographical
contrast amplified by a metal-organic build-up reaction. The re-
sulting nanowell template was incubated with OAs-containing
RNA, to allow its hybridization to ssDNA exposed on the
bottom of the holes. After assembly-competent CP was applied,
TMV-like rods were detected protruding in almost upright
orientations (Figure 8B). Further improvements of the proce-
dure might lead towards tight spatial control over the positions
of the enzyme nanocarriers, which could be of high interest
also for basic research on prerequisites for efficient enzymatic
cooperation.
Fast, sensitive and cost-saving biosensors often employ label-
free read-out, in which signal transduction occurs without a
need of reporter molecules, e.g., by optical, electrochemical,
mass- or surface plasmon resonance-sensitive techniques
[171,172]. The development of site-selective and highly effi-
cient methods for the application of TMV on inorganic or poly-
meric surfaces (Figure 9) has paved the way for the use of TMV
derivatives as adapter scaffolds for sensor enzymes, or as recep-
tor layers for bioaffinity-based recognition in advanced sensor
configurations. Last year, a fundamental study evidenced that a
capture of target molecules by engineered TMV-like particles,
deposited on optical microdisc resonators, was readily
detectable through changes in the effective refractive index of
the waveguide setup and the concomitant shifts in the resonant
wavelength of the sensor cavity, with signal amplification
through label-free enzyme-linked immunosorbent assay
(ELISA) [134]. The sensor system utilized RNA-free TMV-like
rod assemblies fashioned with antigenic peptides as receptor
layer, serving as haptens for the binding of specific antibodies.
Its further development aims primarily at the construction of
widely applicable biosensing devices recording biological anti-
body-target interactions, as they are used in numerous diag-
nostic routines. Label-free biodetection systems exploiting the
beneficial effects of TMV adapter scaffolds carrying sensor en-
zymes are in the pipeline of current research efforts as well, and
might promote novel diagnostic layouts for smaller, non-anti-
genic but bioconvertible analytes.
Conclusion
TMV has accompanied human history for more than a century,
threatening farmers and the tobacco industry as well as support-
ing and inspiring scientists. Once a key player in the origins of
the virology discipline, enabling breakthrough findings on virus
structure, properties and interplay with the host, concomitantly
advancing the development of analytical techniques, the virus
currently adapts novel roles: As a richly available, particularly
robust biomolecular complex, TMV allows for extensive explo-
ration studies on prospects and definite limitations of novel syn-
thetic, nanostructured protein-containing material combinations.
With respect to the general knowledge that a lot of frogs need to
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Figure 9: Arrays of TMV nanorods established by bottom-up or top-down approaches: Site-selectively arranged carriers for uses in biosensor
devices. A: Spatially selective bottom-up growth of terminally immobilized TMV-like particles on aldehyde-modified areas of wafers, fashioned with
assembly-directing RNA. After decoration with bioactive molecules, such arrays ensure stable interlinkage of technical surfaces and biological effector
molecules. Adapted with permission from [54], copyright (2011) American Chemical Society. B: Engineered TMV-like particles coating the waveguide
setup of an optical disk resonator serve as receptor layer for label-free biosensing. Analyte capture induces a shift in the resonant wavelength of the
sensor cavity as a whole. Reproduced and adapted with permission from [134], copyright 2015 IOP Publishing. See text for additional information.
be kissed (or, originally spoken, thrown at a wall) before
meeting a handsome prince [180], research on advantageous ap-
plications of TMV nanorods has yielded exceptionally promis-
ing perspectives in a fairly short period of time. These have
been outlined throughout this review, against the background
of typical problems encountered upon modifying viral
constituents, and in relation to progress obtained with distinct
elongated plant viral backbones.
It is only within the past few years that plant-made effector pro-
teins, pharmaceuticals and virus-like particles especially for
vaccination purposes are regarded economically valuable,
attractive alternatives to conventionally produced compounds.
This is attested by a rapidly growing number of present reports
and companies specializing in this field [181-184]. Plant viral
templates seem to exhibit convincing and in several aspects
unique capacities for the immobilization and stabilization of
bioactive peptides and proteins such as antibodies and enzymes,
as illustrated above. Hence, the newly available rapid transient
production methods in plants used as bioreactors [181] may be
expected to promote the integration of viral nanocarriers in
diagnostic systems and biosensor devices. Among those, the
rigid TMV rods excel in their stable adjustable shape and dura-
bility. After simple conjugation of biotin linkers, they could be
equipped with commercially available, fully active enzyme
preparations at so far unsurpassed surface densities; their per-
formance was even stabilized over weeks. Antibodies were
installed with high efficiencies on TMV backbones as well, by
protein A-exposing CP variants or suitable affinity tags. In
conjunction with a plentitude of protocols established for the
deposition of TMV on technical surfaces, it is thus likely that
TMV will take over routine jobs in appropriate layouts in
the longer run, and continue to forge ahead in encouraging
novel concepts in biodetection, catalysis, electronics and further
applications.
Acknowledgements
We thank Rebecca Hummel and Sigrid Kober for the prepara-
tion of TMV, and Diether Gotthardt for taking care of the
plants. For providing access to and maintaining TEM facilities
we thank Prof. Dr. Stephan Nußberger and PD Dr. Michael
Schweikert. Discussions with Angela Schneider, Nana Wenz,
Klara Altintoprak and Martin Paul were always of great help.
We acknowledge the Baden-Wuerttemberg-Stiftung, Network
of Competence: Functional Nanostructures (KFN) for funding
and the DFG (SPP1569) and the Carl-Zeiss Stiftung and
the University of Stuttgart (Projekthaus NanoBioMater)
for subsidiary financial support, furthermore the Spanish
MINECO (MAT2013-46006-R) and the Basque Government
(PI-2013 57).
References
1. Singh, P.; Gonzalez, M. J.; Manchester, M. Drug Dev. Res. 2006, 67,
23–41. doi:10.1002/ddr.20064
2. Steinmetz, N. F.; Evans, D. J. Org. Biomol. Chem. 2007, 5,
2891–2902. doi:10.1039/b708175h
3. Young, M.; Willits, D.; Uchida, M.; Douglas, T.
Annu. Rev. Phytopathol. 2008, 46, 361–384.
doi:10.1146/annurev.phyto.032508.131939
4. Lee, L. A.; Niu, Z.; Wang, Q. Nano Res. 2009, 2, 349–364.
doi:10.1007/s12274-009-9033-8
5. Bittner, A. M.; Alonso, J. M.; Górzny, M. Ł.; Wege, C. Nanoscale
Science and Technology with Plant Viruses and Bacteriophages. In
Structure and physics of viruses: an integrated textbook;
Mateu, M. G., Ed.; Subcellular Biochemistry, Vol. 68; Springer: Berlin,
Germany, 2013; pp 667–702. doi:10.1007/978-94-007-6552-8_22
6. Glasgow, J.; Tullman-Ercek, D. Appl. Microbiol. Biotechnol. 2014, 98,
5847–5858. doi:10.1007/s00253-014-5787-3
Beilstein J. Nanotechnol. 2016, 7, 613–629.
626
7. Culver, J. N.; Brown, A. D.; Zang, F.; Gnerlich, M.; Gerasopoulos, K.;
Ghodssi, R. Virology 2015, 479–480, 200–212.
doi:10.1016/j.virol.2015.03.008
8. Liu, Z.; Qiao, J.; Niu, Z.; Wang, Q. Chem. Soc. Rev. 2012, 41,
6178–6194. doi:10.1039/c2cs35108k
9. Dimmock, N. J.; Easton, A. J.; Leppard, K. N. Introduction to Modern
Virology, 6th ed.; Blackwell Publishing Limited: Oxford, United
Kingdom, 2007.
10. Wege, C.; Gotthardt, R. D.; Frischmuth, T.; Jeske, H. Arch. Virol.
2000, 145, 2217–2225. doi:10.1007/s007050070052
11. Norrby, E. Arch. Virol. 2008, 153, 1109–1123.
doi:10.1007/s00705-008-0088-8
12. Wildy, P. Classification and Nomenclature of Viruses. First report of
the International Committee on Nomenclature of Viruses. Monographs
in Virology; Karger: Basel, Switzerland, 1971; Vol. 5, pp 82 ff.
13. King, A. M. Q.; Adams, M. J.; Carstens, E. B.; Lefkowitz, E. J. Virus
taxonomy. Classification and nomenclature of viruses. Ninth report of
the International Committee on Taxonomy of Viruses; Elsevier:
Amsterdam, Netherlands, 2012.
14. Lefkowitz, E. J. In Species 2000 & ITIS Catalogue of Life, 23rd
December 2015; digital resource at http://www.catalogueoflife.org/col;
Roskov, Y.; Abucay, L.; Orrell, T.; Nicolson, D.; Kunze, T.; Flann, C.;
Bailly, N.; Kirk, P.; Bourgoin, T.; DeWalt, R. E.; Decock, W.;
De Wever, A., Eds.; Naturalis: Leiden, Netherlands, 2016.
15. TT viruses: The still elusive human pathogens. In Current Topics in
Microbiology and Immunology; zur Hausen, H.; de Villiers, E.-M.,
Eds.; Springer: Berlin, Germany, 2009; Vol. 331.
doi:10.1007/978-3-540-70972-5
16. Ryan, F. Virolution. The most important evolutionary book since
Dawkins' selfish gene; HarperCollins: New York, NY, U.S.A., 2009;
pp 356 ff.
17. Adams, M. J.; Heinze, C.; Jackson, A. O.; Kreuze, J. F.;
MacFarlane, S. A.; Torrance, L. In Virus taxonomy. Classification and
nomenclature of viruses. Ninth report of the international committee
on taxonomy of viruses; King, A. M. Q.; Adams, M. J.; Carstens, E. B.;
Lefkowitz, E. J., Eds.; Elsevier: Amsterdam, Netherlands, 2012;
pp 1139–1162.
18. Mayer, A. Landwirtsch. Vers.-Stn. 1886, 32, 451–467.
19. Ivanowski, D. Bull. Acad. Imp. Sci. St.-Petersbourg 1892, 35, 67–70.
20. Beijerinck, M. W. Verh. K. Akad. Wet. Amsterdam, Afd. Natuurkd.
1898, 5, 3–21.
21. Lustig, A.; Levine, A. J. J. Virol. 1992, 66, 4629–4631.
22. Zaitlin, M. The Discovery of the Causal Agent of the Tobacco Mosaic
Disease. In Discoveries in Plant Biology; Kung, S.-D.; Yan, S.-F.,
Eds.; World Scientific Publishing Co Pte Ltd: Singapore, 1998; Vol. 1,
pp 105–110. doi:10.1142/9789812817563_0007
23. Stanley, W. M.; Loring, H. S. Science 1936, 83, 85.
doi:10.1126/science.83.2143.85
24. Stanley, W. M. Science 1935, 81, 644–645.
doi:10.1126/science.81.2113.644
25. Bawden, F. C.; Pirie, N. W.; Bernal, J. D.; Fankuchen, I. Nature 1936,
138, 1051–1052. doi:10.1038/1381051a0
26. Bawden, F. C.; Pirie, N. W. Proc. R. Soc. London, Ser. B 1937, 123,
274–320. doi:10.1098/rspb.1937.0054
27. Kausche, G. A.; Pfankuch, E.; Ruska, H. Naturwissenschaften 1939,
27, 292–299. doi:10.1007/bf01493353
28. Creager, A. N. H.; Morgan, G. J. Isis 2008, 99, 239–272.
doi:10.1086/588626
29. Butler, P. J. G. J. Mol. Biol. 1974, 82, 343–353.
doi:10.1016/0022-2836(74)90594-4
30. Lomonossoff, G. P.; Butler, P. J. G. Eur. J. Biochem. 1979, 93,
157–164. doi:10.1111/j.1432-1033.1979.tb12806.x
31. Lomonossoff, G. P.; Butler, P. J. G. FEBS Lett. 1980, 113, 271–274.
doi:10.1016/0014-5793(80)80607-7
32. Butler, P. J. G.; Klug, A. Nature (London), New Biol. 1971, 229,
47–50. doi:10.1038/newbio229047a0
33. Butler, P. J. G. Philos. Trans. R. Soc. London, Ser. B 1999, 354,
537–550. doi:10.1098/rstb.1999.0405
34. Okada, Y. Philos. Trans. R. Soc. London, Ser. B 1999, 354, 569–582.
doi:10.1098/rstb.1999.0408
35. Butler, P. J. G. J. Gen. Virol. 1984, 65, 253–279.
doi:10.1099/0022-1317-65-2-253
36. Caspar, D. L. D.; Namba, K. Adv. Biophys. 1990, 26, 157–185.
37. Harrison, B. D.; Wilson, T. M. A. Philos. Trans. R. Soc., B 1999, 354,
521–529. doi:10.1098/rstb.1999.0403
38. Goelet, P.; Lomonossoff, G. P.; Butler, P. J.; Akam, M. E.; Gait, M. J.;
Karn, J. Proc. Natl. Acad. Sci. U. S. A. 1982, 79, 5818–5822.
doi:10.1073/pnas.79.19.5818
39. Fraenkel-Conrat, H.; Williams, R. C. Proc. Natl. Acad. Sci. U. S. A.
1955, 41, 690–698. doi:10.1073/pnas.41.10.690
40. Fraenkel-Conrat, H.; Singer, B. Biochim. Biophys. Acta 1959, 33,
359–370. doi:10.1016/0006-3002(59)90126-X
41. Fraenkel-Conrat, H.; Singer, B. Philos. Trans. R. Soc. London, Ser. B
1999, 354, 583–586. doi:10.1098/rstb.1999.0409
42. Harrison, B. D.; Wilson, T. M. A., Eds. Tobacco mosaic virus:
pioneering research for a century. A meeting held on 7 and 8 August
1998 by the Royal Society of Edinburgh in association with the Royal
Society of London. Philos. Trans. R. Soc., B 1999, 354, 519–685.
doi:10.1098/rstb.1999.0402
43. Gelderblom, H. R.; Krüger, D. H. Adv. Imaging Electron Phys. 2014,
182, 1–94. doi:10.1016/B978-0-12-800146-2.00001-1
44. Caspar, D. L. D. Adv. Protein Chem. 1963, 18, 37–121.
doi:10.1016/S0065-3233(08)60268-5
45. Namba, K.; Pattanayek, R.; Stubbs, G. J. Mol. Biol. 1989, 208,
307–325. doi:10.1016/0022-2836(89)90391-4
46. Fromm, S. A.; Bharat, T. A. M.; Jakobi, A. J.; Hagen, W. J. H.;
Sachse, C. J. Struct. Biol. 2015, 189, 87–97.
doi:10.1016/j.jsb.2014.12.002
47. Culver, J. N. Annu. Rev. Phytopathol. 2002, 40, 287–308.
doi:10.1146/annurev.phyto.40.120301.102400
48. Butler, P. J. G. Nature 1971, 233, 25–27. doi:10.1038/233025a0
49. Turner, D. R.; Butler, P. J. G. Nucleic Acids Res. 1986, 14,
9229–9242. doi:10.1093/nar/14.23.9229
50. Turner, D. R.; McGuigan, C. J.; Butler, P. J. G. J. Mol. Biol. 1989, 209,
407–422. doi:10.1016/0022-2836(89)90006-5
51. Butler, P. J.; Finch, J. T.; Zimmern, D. Nature 1977, 265, 217–219.
doi:10.1038/265217a0
52. Zimmern, D. EMBO J. 1983, 2, 1901–1907.
53. Tobacco mosaic virus.
http://www.dpvweb.net/dpv/showdpv.php?dpvno=370 (accessed Feb
8, 2016).
54. Mueller, A.; Eber, F. J.; Azucena, C.; Petershans, A.; Bittner, A. M.;
Gliemann, H.; Jeske, H.; Wege, C. ACS Nano 2011, 5, 4512–4520.
doi:10.1021/nn103557s
55. Kadri, A.; Wege, C.; Jeske, H. J. Virol. Methods 2013, 189, 328–340.
doi:10.1016/j.jviromet.2013.02.017
56. Rego, J. M.; Lee, J.-H.; Lee, D. H.; Yi, H. Biotechnol. J. 2013, 8,
237–246. doi:10.1002/biot.201100504
57. Eber, F. J.; Eiben, S.; Jeske, H.; Wege, C. Angew. Chem., Int. Ed.
2013, 52, 7203–7207. doi:10.1002/anie.201300834
Beilstein J. Nanotechnol. 2016, 7, 613–629.
627
58. Eber, F. J.; Eiben, S.; Jeske, H.; Wege, C. Nanoscale 2015, 7,
344–355. doi:10.1039/c4nr05434b
59. Wu, Z.; Mueller, A.; Degenhard, S.; Ruff, S. E.; Geiger, F.;
Bittner, A. M.; Wege, C.; Krill, C. E., III. ACS Nano 2010, 4,
4531–4538. doi:10.1021/nn100645e
60. Azucena, C.; Eber, F. J.; Trouillet, V.; Hirtz, M.; Heissler, S.;
Franzreb, M.; Fuchs, H.; Wege, C.; Gliemann, H. Langmuir 2012, 28,
14867–14877. doi:10.1021/la302774h
61. Geiger, F. C.; Eber, F. J.; Eiben, S.; Mueller, A.; Jeske, H.;
Spatz, J. P.; Wege, C. Nanoscale 2013, 5, 3808–3816.
doi:10.1039/c3nr33724c
62. Eiben, S.; Stitz, N.; Eber, F.; Wagner, J.; Atanasova, P.; Bill, J.;
Wege, C.; Jeske, H. Virus Res. 2014, 180, 92–96.
doi:10.1016/j.virusres.2013.11.019
63. Douglas, T.; Young, M. Adv. Mater. 1999, 11, 679–681.
doi:10.1002/(SICI)1521-4095(199906)11:8<679::AID-ADMA679>3.0.
CO;2-J
64. Mao, C.; Liu, A.; Cao, B. Angew. Chem., Int. Ed. 2009, 48,
6790–6810. doi:10.1002/anie.200900231
65. Soto, C. M.; Ratna, B. R. Curr. Opin. Biotechnol. 2010, 21, 426–438.
doi:10.1016/j.copbio.2010.07.004
66. Bernard, J. M. L.; Francis, M. B. Front. Microbiol. 2014, 5, 734.
doi:10.3389/fmicb.2014.00734
67. Alonso, J. M.; Górzny, M. Ł.; Bittner, A. M. Trends Biotechnol. 2013,
31, 530–538. doi:10.1016/j.tibtech.2013.05.013
68. Lee, S.-Y.; Lim, J.-S.; Harris, M. T. Biotechnol. Bioeng. 2012, 109,
16–30. doi:10.1002/bit.23328
69. Capek, I. Adv. Colloid Interface Sci. 2015, 222, 119–134.
doi:10.1016/j.cis.2014.04.008
70. Khudyakov, Y.; Pumpens, P., Eds. Viral Nanotechnology; CRC Press:
Boca Raton, FL, U.S.A., 2015. doi:10.1201/b18596
71. Pushko, P.; Pumpens, P.; Grens, E. Intervirology 2013, 56, 141–165.
doi:10.1159/000346773
72. Putri, R. M.; Cornelissen, J. J. L. M.; Koay, M. S. T. ChemPhysChem
2015, 16, 911–918. doi:10.1002/cphc.201402722
73. Cruz, S. S.; Chapman, S.; Roberts, A. G.; Roberts, I. M.; Prior, D. A.;
Oparka, K. J. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 6286–6290.
doi:10.1073/pnas.93.13.6286
74. Gillitzer, E.; Willits, D.; Young, M.; Douglas, T. Chem. Commun. 2002,
2390–2391. doi:10.1039/B207853H
75. Lewis, J. D.; Destito, G.; Zijlstra, A.; Gonzalez, M. J.; Quigley, J. P.;
Manchester, M.; Stuhlmann, H. Nat. Med. 2006, 12, 354–360.
doi:10.1038/nm1368
76. Martin, B. D.; Soto, C. M.; Blum, A. S.; Sapsford, K. E.; Whitley, J. L.;
Johnson, J. E.; Chatterji, A.; Ratna, B. R. J. Nanosci. Nanotechnol.
2006, 6, 2451–2460. doi:10.1166/jnn.2006.548
77. Chackerian, B. Expert Rev. Vaccines 2007, 6, 381–390.
doi:10.1586/14760584.6.3.381
78. Crisci, E.; Bárcena, J.; Montoya, M. Vet. Immunol. Immunopathol.
2012, 148, 211–225. doi:10.1016/j.vetimm.2012.04.026
79. Kushnir, N.; Streatfield, S. J.; Yusibov, V. Vaccine 2012, 31, 58–83.
doi:10.1016/j.vaccine.2012.10.083
80. Arcangeli, C.; Circelli, P.; Donini, M.; Aljabali, A. A. A.; Benvenuto, E.;
Lomonossoff, G. P.; Marusic, C. J. Biomol. Struct. Dyn. 2014, 32,
630–647. doi:10.1080/07391102.2013.785920
81. Malyutin, A. G.; Easterday, R.; Lozovyy, Y.; Spilotros, A.; Cheng, H.;
Sanchez-Felix, O. R.; Stein, B. D.; Morgan, D. G.; Svergun, D. I.;
Dragnea, B.; Bronstein, L. M. Chem. Mater. 2015, 27, 327–335.
doi:10.1021/cm504029j
82. Wen, A. M.; Wang, Y.; Jiang, K.; Hsu, G. C.; Gao, H.; Lee, K. L.;
Yang, A. C.; Yu, X.; Simon, D. I.; Steinmetz, N. F. J. Mater. Chem. B
2015, 3, 6037–6045. doi:10.1039/c5tb00879d
83. Yildiz, I.; Shukla, S.; Steinmetz, N. F. Curr. Opin. Biotechnol. 2011,
22, 901–908. doi:10.1016/j.copbio.2011.04.020
84. Aniagyei, S. E.; Dufort, C.; Kao, C. C.; Dragnea, B. J. Mater. Chem.
2008, 18, 3763–3774. doi:10.1039/b805874c
85. Manchester, M.; Singh, P. Adv. Drug Delivery Rev. 2006, 58,
1505–1522. doi:10.1016/j.addr.2006.09.014
86. Lin, B.; Ratna, B., Eds. Virus Hybrids as Nanomaterials; Methods in
Molecular Biology, Vol. 1108; Springer: Berlin, Germany, 2014.
doi:10.1007/978-1-62703-751-8
87. Werner, S.; Marillonnet, S.; Hause, G.; Klimyuk, V.; Gleba, Y.
Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 17678–17683.
doi:10.1073/pnas.0608869103
88. Pille, J.; Cardinale, D.; Carette, N.; Di Primo, C.; Besong-Ndika, J.;
Walter, J.; Lecoq, H.; van Eldijk, M. B.; Smits, F. C. M.; Schoffelen, S.;
van Hest, J. C. M.; Mäkinen, K.; Michon, T. Biomacromolecules 2013,
14, 4351–4359. doi:10.1021/bm401291u
89. Li, F.; Wang, Q. Small 2014, 10, 230–245.
doi:10.1002/smll.201301393
90. Love, A. J.; Makarov, V.; Yaminsky, I.; Kalinina, N. O.;
Taliansky, M. E. Virology 2014, 449, 133–139.
doi:10.1016/j.virol.2013.11.002
91. Fan, X. Z.; Pomerantseva, E.; Gnerlich, M.; Brown, A.;
Gerasopoulos, K.; McCarthy, M.; Culver, J.; Ghodssi, R.
J. Vac. Sci. Technol., A 2013, 31, 050815. doi:10.1116/1.4816584
92. Vilona, D.; Di Lorenzo, R.; Carraro, M.; Licini, G.; Trainotti, L.;
Bonchio, M. J. Mater. Chem. B 2015, 3, 6718–6730.
doi:10.1039/c5tb00924c
93. Knez, M.; Sumser, M.; Bittner, A. M.; Wege, C.; Jeske, H.;
Martin, T. P.; Kern, K. Adv. Funct. Mater. 2004, 14, 116–124.
doi:10.1002/adfm.200304376
94. Kadri, A.; Maiss, E.; Amsharov, N.; Bittner, A. M.; Balci, S.; Kern, K.;
Jeske, H.; Wege, C. Virus Res. 2011, 157, 35–46.
doi:10.1016/j.virusres.2011.01.014
95. Manocchi, A. K.; Horelik, N. E.; Lee, B.; Yi, H. Langmuir 2010, 26,
3670–3677. doi:10.1021/la9031514
96. Knez, M.; Bittner, A. M.; Boes, F.; Wege, C.; Jeske, H.; Maiβ, E.;
Kern, K. Nano Lett. 2003, 3, 1079–1082. doi:10.1021/nl0342545
97. Balci, S.; Bittner, A. M.; Schirra, M.; Thonke, K.; Sauer, R.; Hahn, K.;
Kadri, A.; Wege, C.; Jeske, H.; Kern, K. Electrochim. Acta 2009, 54,
5149–5154. doi:10.1016/j.electacta.2009.03.036
98. Zhou, K.; Zhang, J.; Wang, Q. Small 2015, 11, 2505–2509.
doi:10.1002/smll.201401512
99. Lee, S.-Y.; Choi, J.; Royston, E.; Janes, D. B.; Culver, J. N.;
Harris, M. T. J. Nanosci. Nanotechnol. 2006, 6, 974–981.
doi:10.1166/Jnn.2006.146
100.Lewis, C. L.; Lin, Y.; Yang, C.; Manocchi, A. K.; Yuet, K. P.;
Doyle, P. S.; Yi, H. Langmuir 2010, 26, 13436–13441.
doi:10.1021/la102446n
101.Kausche, G. A. Biol. Zentralbl. 1940, 60, 179–199.
102.Shenton, W.; Douglas, T.; Young, M.; Stubbs, G.; Mann, S.
Adv. Mater. 1999, 11, 253–256.
doi:10.1002/(Sici)1521-4095(199903)11:3<253::Aid-Adma253>3.0.Co
;2-7
103.Atanasova, P.; Rothenstein, D.; Schneider, J. J.; Hoffmann, R. C.;
Dilfer, S.; Eiben, S.; Wege, C.; Jeske, H.; Bill, J. Adv. Mater. 2011, 23,
4918–4922. doi:10.1002/adma.201102900
Beilstein J. Nanotechnol. 2016, 7, 613–629.
628
104.Royston, E. S.; Brown, A. D.; Harris, M. T.; Culver, J. N.
J. Colloid Interface Sci. 2009, 332, 402–407.
doi:10.1016/j.jcis.2008.12.064
105.Altintoprak, K.; Seidenstücker, A.; Welle, A.; Eiben, S.; Atanasova, P.;
Stitz, N.; Plettl, A.; Bill, J.; Gliemann, H.; Jeske, H.; Rothenstein, D.;
Geiger, F.; Wege, C. Beilstein J. Nanotechnol. 2015, 6, 1399–1412.
doi:10.3762/bjnano.6.145
106.Witus, L. S.; Francis, M. B. Acc. Chem. Res. 2011, 44, 774–783.
doi:10.1021/ar2001292
107.Royston, E.; Ghosh, A.; Kofinas, P.; Harris, M. T.; Culver, J. N.
Langmuir 2008, 24, 906–912. doi:10.1021/la7016424
108.Chen, X.; Gerasopoulos, K.; Guo, J. C.; Brown, A.; Ghodssi, R.;
Culver, J. N.; Wang, C. Electrochim. Acta 2011, 56, 5210–5213.
doi:10.1016/j.electacta.2011.03.037
109.Chiang, C.-Y.; Epstein, J.; Brown, A.; Munday, J. N.; Culver, J. N.;
Ehrman, S. Nano Lett. 2012, 12, 6005–6011. doi:10.1021/nl303579z
110.Atanasova, P.; Stitz, N.; Sanctis, S.; Maurer, J. H. M.;
Hoffmann, R. C.; Eiben, S.; Jeske, H.; Schneider, J. J.; Bill, J.
Langmuir 2015, 31, 3897–3903. doi:10.1021/acs.langmuir.5b00700
111.Love, A. J.; Makarov, V. V.; Sinitsyna, O. V.; Shaw, J.;
Yaminsky, I. V.; Kalinina, N. O.; Taliansky, M. E. Front. Plant Sci.
2015, 6, 984. doi:10.3389/fpls.2015.00984
112.Tseng, R. J.; Tsai, C.; Ma, L.; Ouyang, J.; Ozkan, C. S.; Yang, Y.
Nat. Nanotechnol. 2006, 1, 72–77. doi:10.1038/nnano.2006.55
113.Yang, C.; Choi, C.-H.; Lee, C.-S.; Yi, H. ACS Nano 2013, 7,
5032–5044. doi:10.1021/Nn4005582
114.Schlick, T. L.; Ding, Z.; Kovacs, E. W.; Francis, M. B.
J. Am. Chem. Soc. 2005, 127, 3718–3723. doi:10.1021/ja046239n
115.Demir, M.; Stowell, M. H. B. Nanotechnology 2002, 13, 541–544.
doi:10.1088/0957-4484/13/4/318
116.Bruckman, M. A.; Randolph, L. N.; Gulati, N. M.; Stewart, P. L.;
Steinmetz, N. F. J. Mater. Chem. B 2015, 3, 7503–7510.
doi:10.1039/c5tb01014d
117.Shukla, S.; Eber, F. J.; Nagarajan, A. S.; DiFranco, N. A.; Schmidt, N.;
Wen, A. M.; Eiben, S.; Twyman, R. M.; Wege, C.; Steinmetz, N. F.
Adv. Healthcare Mater. 2015, 4, 874–882.
doi:10.1002/adhm.201400641
118.Wen, A. M.; Lee, K. L.; Yildiz, I.; Bruckman, M. A.; Shukla, S.;
Steinmetz, N. F. J. Visualized Exp. 2012, e4352. doi:10.3791/4352
119.Zahr, O. K.; Blum, A. S. Nano Lett. 2012, 12, 629–633.
doi:10.1021/nl203368v
120.Miller, R. A.; Presley, A. D.; Francis, M. B. J. Am. Chem. Soc. 2007,
129, 3104–3109. doi:10.1021/ja063887t
121.Niehl, A.; Appaix, F.; Boscá, S.; van der Sanden, B.; Nicoud, J.-F.;
Bolze, F.; Heinlein, M. Front. Plant Sci. 2015, 6, 1244.
doi:10.3389/fpls.2015.01244
122.Luckanagul, J. A.; Lee, L. A.; You, S.; Yang, X.; Wang, Q.
J. Biomed. Mater. Res., Part A 2015, 103, 887–895.
doi:10.1002/jbm.a.35227
123.Kaur, G.; Wang, C.; Sun, J.; Wang, Q. Biomaterials 2010, 31,
5813–5824. doi:10.1016/j.biomaterials.2010.04.017
124.Bruckman, M. A.; Jiang, K.; Simpson, E. J.; Randolph, L. N.;
Luyt, L. G.; Yu, X.; Steinmetz, N. F. Nano Lett. 2014, 14, 1551–1558.
doi:10.1021/nl404816m
125.Smith, M. L.; Lindbo, J. A.; Dillard-Telm, S.; Brosio, P. M.;
Lasnik, A. B.; McCormick, A. A.; Nguyen, L. V.; Palmer, K. E. Virology
2006, 348, 475–488. doi:10.1016/j.virol.2005.12.039
126.Turpen, T. H.; Reinl, S. J.; Charoenvit, Y.; Hoffman, S. L.;
Fallarme, V.; Grill, L. K. Nat. Biotechnol. 1995, 13, 53–57.
doi:10.1038/nbt0195-53
127.Karpova, O.; Nikitin, N.; Chirkov, S.; Trifonova, E.; Sheveleva, A.;
Lazareva, E.; Atabekov, J. J. Gen. Virol. 2012, 93, 400–407.
doi:10.1099/vir.0.036293-0
128.McCormick, A. A.; Palmer, K. E. Expert Rev. Vaccines 2008, 7,
33–41. doi:10.1586/14760584.7.1.33
129.Banik, S.; Mansour, A. A.; Suresh, R. V.; Wykoff-Clary, S.; Malik, M.;
McCormick, A. A.; Bakshi, C. S. PLoS One 2015, 10, e0130858.
doi:10.1371/journal.pone.0130858
130.Cardinale, D.; Carette, N.; Michon, T. Trends Biotechnol. 2012, 30,
369–376. doi:10.1016/j.tibtech.2012.04.001
131.Cardinale, D.; Michon, T., Eds. Enzyme nanocarriers; CRC Press:
Boca Raton, FL, U.S.A., 2015. doi:10.1201/b18970
132.Koch, C.; Wabbel, K.; Eber, F. J.; Krolla-Sidenstein, P.; Azucena, C.;
Gliemann, H.; Eiben, S.; Geiger, F.; Wege, C. Front. Plant Sci. 2015,
6, 1137. doi:10.3389/fpls.2015.01137
133.Hou, C.; Luo, Q.; Liu, J.; Miao, L.; Zhang, C.; Gao, Y.; Zhang, X.;
Xu, J.; Dong, Z.; Liu, J. ACS Nano 2012, 6, 8692–8701.
doi:10.1021/nn302270b
134.Fan, X. Z.; Naves, L.; Siwak, N. P.; Brown, A.; Culver, J.; Ghodssi, R.
Nanotechnology 2015, 26, 205501.
doi:10.1088/0957-4484/26/20/205501
135.Yi, H.; Nisar, S.; Lee, S.-Y.; Powers, M. A.; Bentley, W. E.;
Payne, G. F.; Ghodssi, R.; Rubloff, G. W.; Harris, M. T.; Culver, J. N.
Nano Lett. 2005, 5, 1931–1936. doi:10.1021/nl051254r
136.Yi, H.; Rubloff, G. W.; Culver, J. N. Langmuir 2007, 23, 2663–2667.
doi:10.1021/la062493c
137.Tan, W. S.; Lewis, C. L.; Horelik, N. E.; Pregibon, D. C.; Doyle, P. S.;
Yi, H. Langmuir 2008, 24, 12483–12488. doi:10.1021/la802089q
138.McCormick, A. A.; Corbo, T. A.; Wykoff-Clary, S.; Nguyen, L. V.;
Smith, M. L.; Palmer, K. E.; Pogue, G. P. Vaccine 2006, 24,
6414–6423. doi:10.1016/j.vaccine.2006.06.003
139.Luckanagul, J.; Lee, L. A.; Nguyen, Q. L.; Sitasuwan, P.; Yang, X.;
Shazly, T.; Wang, Q. Biomacromolecules 2012, 13, 3949–3958.
doi:10.1021/bm301180c
140.Lee, L. A.; Nguyen, Q. L.; Wu, L.; Horvath, G.; Nelson, R. S.;
Wang, Q. Biomacromolecules 2012, 13, 422–431.
doi:10.1021/bm2014558
141.Pomerantseva, E.; Gerasopoulos, K.; Chen, X.; Rubloff, G. W.;
Ghodssi, R. J. Power Sources 2012, 206, 282–287.
doi:10.1016/j.jpowsour.2012.01.127
142.Sassolas, A.; Blum, L. J.; Leca-Bouvier, B. D. Biotechnol. Adv. 2012,
30, 489–511. doi:10.1016/j.biotechadv.2011.09.003
143.Liu, W.; Wang, L.; Jiang, R. Top. Catal. 2012, 55, 1146–1156.
doi:10.1007/s11244-012-9893-0
144.Brena, B.; González-Pombo, P.; Batista-Viera, F. Immobilization of
Enzymes: A Literature Survey. In Immobilization of Enzymes and
Cells, 3rd ed.; Guisan, M. J., Ed.; Methods in Molecular Biology, Vol.
1051; Springer: Berlin, Germany, 2013; pp 15–31.
doi:10.1007/978-1-62703-550-7_2
145.Singh, R. K.; Tiwari, M. K.; Singh, R.; Lee, J.-K. Int. J. Mol. Sci. 2013,
14, 1232–1277. doi:10.3390/ijms14011232
146.Katchalski-Katzir, E. Trends Biotechnol. 1993, 11, 471–478.
doi:10.1016/0167-7799(93)90080-S
147.Mateo, C.; Palomo, J. M.; Fernandez-Lorente, G.; Guisan, J. M.;
Fernandez-Lafuente, R. Enzyme Microb. Technol. 2007, 40,
1451–1463. doi:10.1016/j.enzmictec.2007.01.018
148.DiCosimo, R.; McAuliffe, J.; Poulose, A. J.; Bohlmann, G.
Chem. Soc. Rev. 2013, 42, 6437–6474. doi:10.1039/c3cs35506c
149.Friedel, M.; Baumketner, A.; Shea, J.-E. Proc. Natl. Acad. Sci. U. S. A.
2006, 103, 8396–8401. doi:10.1073/pnas.0601210103
Beilstein J. Nanotechnol. 2016, 7, 613–629.
629
150.Cha, T.; Guo, A.; Zhu, X.-Y. Proteomics 2005, 5, 416–419.
doi:10.1002/pmic.200400948
151.Liese, A.; Hilterhaus, L. Chem. Soc. Rev. 2013, 42, 6236–6249.
doi:10.1039/c3cs35511j
152.Aljabali, A. A. A.; Barclay, J. E.; Steinmetz, N. F.; Lomonossoff, G. P.;
Evans, D. J. Nanoscale 2012, 4, 5640–5645. doi:10.1039/c2nr31485a
153.Chatterji, A.; Ochoa, W.; Shamieh, L.; Salakian, S. P.; Wong, S. M.;
Clinton, G.; Ghosh, P.; Lin, T.; Johnson, J. E. Bioconjugate Chem.
2004, 15, 807–813. doi:10.1021/bc0402888
154.Carette, N.; Engelkamp, H.; Akpa, E.; Pierre, S. J.; Cameron, N. R.;
Christianen, P. C. M.; Maan, J. C.; Thies, J. C.; Weberskirch, R.;
Rowan, A. E.; Nolte, R. J. M.; Michon, T.; Van Hest, J. C. M.
Nat. Nanotechnol. 2007, 2, 226–229. doi:10.1038/nnano.2007.76
155.Besong-Ndika, J.; Wahlsten, M.; Cardinale, D.; Pille, J.; Walter, J.;
Michon, T.; Mäkinen, K. Front. Plant Sci. 2016, 7, 89.
doi:10.3389/fpls.2016.00089
156.Minten, I. J.; Claessen, V. I.; Blank, K.; Rowan, A. E.; Nolte, R. J. M.;
Cornelissen, J. J. L. M. Chem. Sci. 2011, 2, 358–362.
doi:10.1039/c0sc00407c
157.Comellas-Aragonès, M.; Engelkamp, H.; Claessen, V. I.;
Sommerdijk, N. A. J. M.; Rowan, A. E.; Christianen, P. C. M.;
Maan, J. C.; Verduin, B. J. M.; Cornelissen, J. J. L. M.; Nolte, R. J. M.
Nat. Nanotechnol. 2007, 2, 635–639. doi:10.1038/nnano.2007.299
158.Vriezema, D. M.; Garcia, P. M. L.; Sancho Oltra, N.; Hatzakis, N. S.;
Kuiper, S. M.; Nolte, R. J. M.; Rowan, A. E.; van Hest, J. C. M.
Angew. Chem., Int. Ed. 2007, 46, 7378–7382.
doi:10.1002/anie.200701125
159.Kuiper, S. M.; Nallani, M.; Vriezema, D. M.; Cornelissen, J. J. L. M.;
van Hest, J. C. M.; Nolte, R. J. M.; Rowan, A. E. Org. Biomol. Chem.
2008, 6, 4315–4318. doi:10.1039/b811196k
160.van Dongen, S. F. M.; Nallani, M.; Cornelissen, J. J. L. M.;
Nolte, R. J. M.; van Hest, J. C. M. Chemistry 2009, 15, 1107–1114.
doi:10.1002/chem.200802114
161.van Dongen, S. F. M.; Verdurmen, W. P. R.; Peters, R. J. R. W.;
Nolte, R. J. M.; Brock, R.; van Hest, J. C. M. Angew. Chem., Int. Ed.
2010, 49, 7213–7216. doi:10.1002/anie.201002655
162.Kalnciema, I.; Balke, I.; Skrastina, D.; Ose, V.; Zeltins, A.
Mol. Biotechnol. 2015, 57, 982–992. doi:10.1007/s12033-015-9891-0
163.Donnelly, M. L. L.; Luke, G.; Mehrotra, A.; Li, X.; Hughes, L. E.;
Gani, D.; Ryan, M. D. J. Gen. Virol. 2001, 82, 1013–1025.
doi:10.1099/0022-1317-82-5-1013
164.Braisted, A. C.; Wells, J. A. Proc. Natl. Acad. Sci. U. S. A. 1996, 93,
5688–5692. doi:10.1073/pnas.93.12.5688
165.Hermanson, G. T. Bioconjugate Techniques, 3rd ed.; Academic
Press: Cambridge, MA, U.S.A., 2013.
doi:10.1016/B978-0-12-382239-0.00025-X
166.Woolridge, E.; Turchi, S. L.; Edwards, J. R. Biochem. Educ. 1986, 14,
82–83. doi:10.1016/0307-4412(86)90073-7
167.Bateman, R. C., Jr.; Evans, J. A. J. Chem. Educ. 1995, 72,
A240–A241. doi:10.1021/ed072pA240
168.Hecht, H. J.; Schomburg, D.; Kalisz, H.; Schmid, R. D.
Biosens. Bioelectron. 1993, 8, 197–203.
doi:10.1016/0956-5663(93)85033-K
169.Azevedo, A. M.; Martins, V. C.; Prazeres, D. M. F.; Vojinović, V.;
Cabral, J. M. S.; Fonseca, L. P. Biotechnol. Annu. Rev. 2003, 9,
199–247. doi:10.1016/S1387-2656(03)09003-3
170.Mark, D.; Haeberle, S.; Roth, G.; von Stetten, F.; Zengerle, R.
Chem. Soc. Rev. 2010, 39, 1153–1182. doi:10.1039/B820557B
171.Lafleur, J. P.; Jönsson, A.; Senkbeil, S.; Kutter, J. P.
Biosens. Bioelectron. 2016, 76, 213–233.
doi:10.1016/j.bios.2015.08.003
172.Rackus, D. G.; Shamsi, M. H.; Wheeler, A. R. Chem. Soc. Rev. 2015,
44, 5320–5340. doi:10.1039/C4CS00369A
173.Brown, A. D.; Culver, J. N. Tobacco Mosaic Virus Assembled High
Aspect Ratio Surfaces. In Virus Hybrids as Nanomaterials: Methods
and Protocols; Lin, B.; Ratna, B., Eds.; Methods in Molecular Biology,
Vol. 1108; Springer: Berlin, Germany, 2014; pp 113–121.
doi:10.1007/978-1-62703-751-8_9
174.Maeda, H. Langmuir 1997, 13, 4150–4161. doi:10.1021/la962105e
175.Balci, S.; Leinberger, D. M.; Knez, M.; Bittner, A. M.; Boes, F.;
Kadri, A.; Wege, C.; Jeske, H.; Kern, K. Adv. Mater. 2008, 20,
2195–2200. doi:10.1002/adma.200602879
176.Knez, M.; Sumser, M. P.; Bittner, A.; Wege, C.; Jeske, H.;
Hoffmann, D. M. P.; Kuhnke, K.; Kern, K. Langmuir 2004, 20,
411–447. doi:10.1021/la035425o
177.Chen, I.-J.; Eckstein, E. C.; Lindner, E. Lab Chip 2009, 9, 107–114.
doi:10.1039/b808660e
178.Huang, C.; Förste, A.; Walheim, S.; Schimmel, T.
Beilstein J. Nanotechnol. 2015, 6, 1205–1211.
doi:10.3762/bjnano.6.123
179.Huang, C.; Moosmann, M.; Jin, J.; Heiler, T.; Walheim, S.;
Schimmel, T. Beilstein J. Nanotechnol. 2012, 3, 620–628.
doi:10.3762/bjnano.3.71
180.Mieder, W. Marvels Tales 2014, 28, 104–126.
doi:10.13110/marvelstales.28.1.0104
181.Marsian, J.; Lomonossoff, G. P. Curr. Opin. Biotechnol. 2016, 37,
201–206. doi:10.1016/j.copbio.2015.12.007
182.Rosales-Mendoza, S.; Angulo, C.; Meza, B. Trends Biotechnol. 2016,
34, 124–136. doi:10.1016/j.tibtech.2015.11.007
183.Sack, M.; Hofbauer, A.; Fischer, R.; Stoger, E. Curr. Opin. Biotechnol.
2015, 32, 163–170. doi:10.1016/j.copbio.2014.12.008
184.Shirbaghaee, Z.; Bolhassani, A. Biopolymers 2016, 105, 113–132.
doi:10.1002/bip.22759
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of
Nanotechnology terms and conditions:
(http://www.beilstein-journals.org/bjnano)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjnano.7.54
